Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety …

Cingulate currently has three (3) product candidates, CTx-1301 (dexmethylphenidate), CTx-1302 (dextroamphetamine) and CTx-2103 (anxiety) in the pipeline. All three therapies utilize Cingulate’s …

Nov 10, 2025 · Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients KANSAS CITY, Kan., Aug. 06, 2025 …

May 20, 2025 · Last month Cingulate announced positive top-line results of a high dose (50-mg) food effect study for CTx-1301, with the primary endpoints establishing that it can be taken with or without …

The Investor Relations website contains information about Cingulate Inc's business for stockholders, potential investors, and financial analysts.

Cingulate’s lead candidate, CTx-1301, is in late-stage development for ADHD, with additional candidates in anxiety and other neuropsychiatric indications. Cingulate is headquartered in Kansas City, Kansas.

Jul 29, 2025 · With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product …

Jun 16, 2025 · Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Cingulate INC SEC filing: Form 8-K on 01/29/2024 (0001493152-24-004061).

The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate’s website at cingulate.com/investors.